MesotheliomaPhase 1NCT06885697
TNhYP218 CAR T Cells
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Ladarixin With Sotorasib in Advanced NSCLC
What the film says
This trial is for adults with advanced non-small cell lung cancer that carries a KRAS G12C mutation.
The idea: add ladarixin, an experimental pill, to sotorasib, an approved targeted drug for this mutation. Both are taken by mouth, in 21 day cycles. The ladarixin dose is raised step by step in small groups of patients.
This phase 1 study plans 40 patients and first looks at dose-limiting side effects. At NYU Langone Health in New York, Salman Punekar leads it.
Public record; not medical advice.
Sources behind this film
Adults; advanced NSCLC with KRAS G12C mutation; Ladarixin added to sotorasib, both by mouth, 21 day cycles; Ladarixin dose escalated in small groups; Phase 1; 40 patients; dose-limiting toxicities first (+1 more lines)
The drug
Sotorasib administered at the approved dose of 960mg PO once daily over 21-day treatment cycles.
Ladarixin dose will be escalated as follows in Phase I: 3 patients will receive a starting dose of 200mg. If 2 or more patients experience a DLT at the lowest dose, the study will stop. If 0 out of 3 patients experience a DLT within 28 days, the next 3 patients will receive 300mg.
This study will enroll patients with KRASG12C mutant NSCLC not previously treated with KRASG12C inhibitors. Patients in this study will receive ladarixin and sotorasib. The primary objective of the Phase I portion is to define a recommended phase II dose (RP2D) of ladarixin when combined with sotorasib. The primary objective of the Phase II portion is to evaluate progression free survival (PFS).
The study
This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in participants with advanced KRASG12C mutant non-small cell lung cancer (NSCLC).
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.